Story
Clariant Upgraded by Goldman Sachs, Berenberg on Reduced Litigation Risk

Swiss specialty chemicals firm Clariant AG (CLN) received upgraded ratings from both Berenberg and Goldman Sachs, who now rate the stock a “Buy” from “Hold.” In separate notes, the analysts cited a significant reduction in litigation risk following a favorable court ruling and an expected recovery in the company's underperforming Catalysts division.
Favorable Ruling Eases Litigation Overhang
A key driver for the upgrades was a late July decision by the Amsterdam District Court, which dismissed a €1 billion damages claim from Shell Chemicals Europe. The claim was related to an alleged ethylene cartel, and the court found no plausible impact on the monthly contract reference price for the chemical.
This ruling materially lessens a major risk for Clariant, which faced aggregate potential claims of roughly €10 billion—about four times its market capitalization. Following the decision, Berenberg cut its litigation reserve estimate for Clariant to CHF 200 million from a previous CHF 900 million. Goldman Sachs stated the development allows the market to now "risk-adjust" the potential liability.
Catalyst Division Poised for Rebound
Both investment banks also highlighted the potential for a turnaround in Clariant's Catalysts segment, which has been a primary drag on recent performance. The division's volumes fell 14.2% year-on-year in the second quarter of 2026, a decline management attributed largely to order delays from the Middle East.
AdGoldman Sachs identified the first quarter of 2026 as the trough for the unit, when its adjusted EBITDA margin fell to 9% from 16% a year earlier. The bank now expects a "Catalysts refill cycle to inflect ahead," signaling a positive outlook for future demand.
Analyst Outlook and Valuation
Both Berenberg and Goldman Sachs issued a matching price target of CHF 12 per share. However, their earnings forecasts diverge, reflecting different views on the speed of the recovery. Goldman's fiscal 2027 EBITDA estimate is 5.8% above the Visible Alpha consensus, while Berenberg's is approximately 5% below consensus.
Goldman's sum-of-the-parts analysis suggests a full value of CHF 17.10 per share, but its lower price target reflects the remaining litigation pending in other European courts. Clariant shares closed Tuesday at CHF 10.04 on the SIX Swiss Exchange, near their 52-week high.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.